Scientific article

Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression

Published inJournal of clinical psychopharmacology, vol. 32, no. 5, p. 622-629
Publication date2012

Pharmacogenetic tests and therapeutic drug monitoring may considerably improve the pharmacotherapy of depression. The aim of this study was to evaluate the relationship between the efficacy of mirtazapine (MIR) and the steady-state plasma concentrations of its enantiomers and metabolites in moderately to severely depressed patients, taking their pharmacogenetic status into account. Inpatients and outpatients (n = 45; mean age, 51 years; range, 19-79 years) with major depressive episode received MIR for 8 weeks (30 mg/d on days 1-14 and 30-45 mg/d on days 15-56). Mirtazapine treatment resulted in a significant improvement in mean Hamilton Depression Rating Scale total score at the end of the study (P < 0.0001). There was no evidence for a significant plasma concentration-clinical effectiveness relationship regarding any pharmacokinetic parameter. The enantiomers of MIR and its hydroxylated (OH-MIR) and demethylated (DMIR) metabolites in plasma samples on days 14 and 56 were influenced by sex and age. Nonsmokers (n = 28) had higher mean MIR plasma levels than smokers (n = 17): S(+)-enantiomer of MIR, 9.4 (SD, 3.9) versus 6.2 (SD, 5.5) ng/mL (P = 0.005); R(-)-enantiomer of MIR, 24.4 (SD, 6.5) versus 18.5 (SD, 4.1) ng/mL (P = 0.003). Only in nonsmokers, plasma levels of S(+)-enantiomer of MIR and metabolites depended on the CYP2D6 genotype. Therefore, high CYP1A2 activity seen in smokers seems to mask the influence of the CYP2D6 genotype. In patients presenting the CYP2B6 *6/*6 genotype (n = 8), S-OH-MIR concentrations were higher those in the other patients (n = 37). Although it is not known if S-OH-MIR is associated with the therapeutic effect of MIR, the reduction of the Hamilton scores was significantly (P = 0.016) more pronounced in the CYP2B6 *6/*6-genotyped patients at the end of the study. The role of CYP2B6 in the metabolism and effectiveness of MIR should be further investigated.

  • Adult
  • Age Factors
  • Aged
  • Antidepressive Agents, Tricyclic/chemistry/pharmacokinetics/therapeutic use
  • Cytochrome P-450 CYP1A2/metabolism
  • Cytochrome P-450 CYP2D6/genetics
  • Depressive Disorder, Major/drug therapy/physiopathology
  • Drug Monitoring/methods
  • Female
  • Genotype
  • Humans
  • Male
  • Mianserin/analogs & derivatives/chemistry/pharmacokinetics/therapeutic use
  • Middle Aged
  • Pharmacogenetics
  • Psychiatric Status Rating Scales
  • Sex Factors
  • Smoking/metabolism
  • Stereoisomerism
  • Treatment Outcome
  • Young Adult
Citation (ISO format)
JAQUENOUD SIROT, Eveline et al. Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. In: Journal of clinical psychopharmacology, 2012, vol. 32, n° 5, p. 622–629. doi: 10.1097/JCP.0b013e3182664d98
Main files (1)
Article (Published version)
ISSN of the journal0271-0749

Technical informations

Creation12/13/2013 11:58:00 AM
First validation12/13/2013 11:58:00 AM
Update time03/14/2023 8:43:50 PM
Status update03/14/2023 8:43:50 PM
Last indexation01/16/2024 8:32:26 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack